SGRYHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering Surgery Partners, Inc. hold a median 12-month price target of $24 — +1.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 3 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Surgery Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (69): Sales and profits are climbing, and climbing faster than before.
Volatility (32): The share price moves around a lot.
Size (30): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SGRY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.5% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | UBS | Downgrade | Neutral | $21 → $24 |
| 27 Oct 2026 | StoneX | Downgrade | Hold | — |
| 30 Sept 2026 | RBC Capital | Reiterates | Outperform | $19 |
| 30 Sept 2026 | RBC Capital | Reiterates | Outperform | — |
| 18 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 18 Sept 2026 | TD Cowen | Reiterates | Buy | $19 |
| 14 Sept 2026 | JP Morgan | Maintains | Neutral | — |
| 14 Sept 2026 | JP Morgan | Maintains | Neutral | $14 → $15 |
| 11 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 11 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $18 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $20 → $19 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | $17 → $19 |
| 5 Mar 2026 | Mizuho | Maintains | Outperform | $19 → $17 |
| 5 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 5 Mar 2026 | TD Cowen | Maintains | Buy | $28 → $20 |
| 5 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 5 Mar 2026 | UBS | Maintains | Buy | $29 → $21 |
| 5 Mar 2026 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SGRY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Surgery Partners, Inc. returned +5.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 70% of US stocks
Cheaper than 46% of US stocks
Cheaper than 27% of US stocks
Higher than 34% of US stocks
Higher than 40% of US stocks
Higher than 24% of US stocks
Higher than 71% of US stocks
Higher than 27% of US stocks
Higher than 48% of US stocks
Higher than 69% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Surgery Partners, Inc. has a market value of $3.0B and an enterprise value of $8.6B.
Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 2.7% year on year.
Net income over the same four quarters: $81.9M, a 2.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.70.
Free cash flow in the twelve months to 30 June 2026: $187.6M.
Trailing P/E: 2956.0×; forward P/E: 111.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Surgery Partners, Inc. employs 16,000 people — $210K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Surgery Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Wohl & Fruchter LLP said it is investigating the fairness of the proposed sale of Surgery Partners to HealthSpan Partners for $23.50 per share in cash.
Why it matters — The investigation concerns the fairness of the proposed transaction and may be relevant to SGRY shareholders following the sale.
Scott+Scott Attorneys at Law LLP is investigating whether Surgery Partners’ directors breached their fiduciary duties to shareholders.
Why it matters — The investigation concerns the conduct of SGRY’s directors and may be relevant to shareholders monitoring the company.
Business Wire published a notice telling Surgery Partners shareholders to contact BFA Law regarding its ongoing investigation into the $23.50-per-share merger.
Why it matters — The notice concerns an investigation related to Surgery Partners’ merger and may be relevant to shareholders following the transaction.
Bleichmar Fonti & Auld LLP announced an investigation into the proposed merger taking Surgery Partners private by Bon Secours Mercy Health. The headline cites a $23.50-per-share merger, and the firm directed current stockholders to its website for additional information.
Why it matters — The investigation concerns the terms of the transaction affecting Surgery Partners shareholders.
Bleichmar Fonti & Auld LLP says it is investigating Surgery Partners’ proposed $23.50-per-share merger with Bon Secours Mercy Health, announced October 26, 2026. Bain Capital, Surgery Partners’ largest stockholder, is rolling its equity into the post-merger entity.
Why it matters — The investigation and proposed going-private merger are relevant to SGRY shareholders assessing the transaction.
The 7 Wall Street analysts covering Surgery Partners, Inc. have a median 12-month price target of $24, with estimates ranging from $19 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Surgery Partners, Inc., 2 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surgery Partners, Inc. 41 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Surgery Partners, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (69 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +1.5% from the last close, and Ticker Nerd's factor model ranks Surgery Partners, Inc. 41 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Surgery Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $24 over the next 12 months.
Surgery Partners, Inc. returned +5.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "SGRY Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Surgery Partners to HealthSpan Partners". Wohl & Fruchter LLP said it is investigating the fairness of the proposed sale of Surgery Partners to HealthSpan Partners for $23.50 per share in cash.
Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States. The company focuses on outpatient and short-stay procedures delivered through ambulatory surgery centers and surgical hospitals, serving patients in specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. Its integrated model also includes anesthesia services, multi-specialty physician practices, diagnostic testing, urgent care facilities, and other ancillary services that support clinical operations. Surgery Partners Inc. plays a significant role in the outpatient care market by connecting providers, facilities, and supporting services within a coordinated healthcare delivery platform. Headquartered in Brentwood, Tennessee, the company serves a wide range of communities through locations in multiple states.
CEO Mr. J. Eric Evans · 16,000 employees · United States · https://www.surgerypartners.com
